Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

Aim: To evaluate the cost utility and budget impact of second-line gefitinib for non-small cell lung cancer from a Thai payer perspective. Methods: A Markov model with three health states (pre-progression, post-progression and death) was constructed to estimate direct medical costs and outcomes comp...

Saved in:

書目詳細資料
Main Authors:	Thongprasert,S., Tinmanee,S., Permsuwan,U.
格式:	Article
出版:	Wiley-Blackwell 2015
主題:	Oncology
在線閱讀:	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84857528545&origin=inward http://cmuir.cmu.ac.th/handle/6653943832/38524
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
由: Thongprasert S., et al.
出版: (2014)

Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
由: Thongprasert S., et al.
出版: (2017)

Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
由: Sumitra Thongprasert, et al.
出版: (2018)

Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
由: Sumitra Thongprasert, et al.
出版: (2018)

Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
由: Unchalee Permsuwan, et al.
出版: (2020)

Cost-utility analysis of dapagliflozin compared to sulfonylureas for type 2 diabetes as second-line treatment in indian healthcare payer’s perspective
由: Bhavani Shankara Bagepally, et al.
出版: (2022)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Wu Y.-L., et al.
出版: (2014)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
由: Ku, G.Y., et al.
出版: (2016)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
由: Wong, A.S., et al.
出版: (2014)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
由: Afrita Amalia Laitupa, -, et al.
出版: (2019)

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
由: De Lima Lopes Jr., G., et al.
出版: (2016)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Fukuoka M., et al.
出版: (2017)

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
由: Tan, P.-T, et al.
出版: (2020)

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
由: Cho B.C.
出版: (2023)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Masahiro Fukuoka, et al.
出版: (2018)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
由: Sudo, M., et al.
出版: (2014)

Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
由: Chaichana Chantharakhit
出版: (2019)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
由: Wong, A.S., et al.
出版: (2014)

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
由: James Chih Hsin Yang, et al.
出版: (2018)

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
由: Mark Boye, et al.
出版: (2018)

Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer
由: Zee, Y.-K., et al.
出版: (2014)

Combination of gemcitabine and cisplatin in advanced non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective
由: Permsuwan U., et al.
出版: (2017)

Short-hairpin RNA library: Identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
由: Sudo M., et al.
出版: (2020)

Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective
由: Unchalee Permsuwan, et al.
出版: (2018)

Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer’s perspective
由: Unchalee Permsuwan, et al.
出版: (2018)

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR plus non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
由: Ma, Jun, et al.
出版: (2024)

Efficacy and tolerability of tropisetron in the prevention of cisplatin-induced nausea and vomiting in advanced non-small cell lung cancer
由: Thongprasert S.
出版: (2014)

Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer
由: Chitapanarux,I., et al.
出版: (2015)

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
由: Mok T., et al.
出版: (2017)

Treatment of advanced non-small cell lung cancer with vinorelbine in elderly Thai patients
由: Sorraritchingchai S., et al.
出版: (2014)

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
由: Tony Mok, et al.
出版: (2018)

Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Wu Y., et al.
出版: (2017)

Paclitaxel and carboplatin plus megestrol acetate in the treatment of advanced non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

HNMT Upregulation Induces Cancer Stem Cell Formation and Confers Protection against Oxidative Stress through Interaction with HER2 in Non-Small-Cell Lung Cancer
由: Kuo, Kuang-Tai, et al.
出版: (2022)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)